Published in Clin Infect Dis on June 25, 2003
Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infect Dis (2007) 1.26
Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis (2004) 1.21
Dengue and its effects on liver. World J Clin Cases (2015) 1.01
Dengue hemorrhagic fever and fulminant hepatic failure. Dig Dis Sci (2005) 0.89
Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccin (2010) 0.87
Significant increase in travel-associated dengue fever in Germany. Med Microbiol Immunol (2011) 0.84
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Cryptococcal meningitis. Br Med Bull (2005) 3.95
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
HIV-associated cryptococcal meningitis. AIDS (2007) 3.18
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 2.99
Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis (2008) 2.87
Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis (2010) 2.85
Phylogenetic relationships and differential selection pressures among genotypes of dengue-2 virus. Virology (2002) 2.75
Poliovirus type 1 in working stocks of typed human rhinoviruses. Lancet (2003) 2.71
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 2.31
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (2012) 2.02
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 1.83
Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol (2007) 1.78
Chronic Q fever: different serological results in three countries--results of a follow-up study 6 years after a point source outbreak. Clin Infect Dis (2011) 1.68
High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS (2009) 1.60
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect (2011) 1.53
Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One (2013) 1.41
Testing for haemochromatosis in a liver clinic population: relationship between ethnic origin, HFE gene mutations, liver histology and serum iron markers. Eur J Gastroenterol Hepatol (2002) 1.40
Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS (2010) 1.35
Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis (2005) 1.30
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis (2010) 1.29
Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect (2010) 1.28
Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol (2002) 1.25
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS (2012) 1.19
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.19
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother (2011) 1.16
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J (2010) 1.16
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother (2006) 1.13
Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathog (2011) 1.13
Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis (2013) 1.12
Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. Emerg Infect Dis (2009) 1.11
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother (2013) 1.09
Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. J Clin Invest (2014) 1.08
The burden of HIV-associated cryptococcal disease. AIDS (2009) 1.08
Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS (2010) 1.07
Co-evolutionary patterns of variation in small and large RNA segments of Crimean-Congo hemorrhagic fever virus. J Gen Virol (2005) 1.05
Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa? S Afr Med J (2011) 1.05
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis (2005) 1.05
Colorectal cancer in the young: trends, characteristics and outcome. Int J Colorectal Dis (2011) 1.04
Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis (2008) 1.02
Acute cytomegalovirus infection complicated by collapsing glomerulopathy. Nephrol Dial Transplant (2003) 1.02
Pulmonary cryptococcosis. Semin Respir Crit Care Med (2008) 0.95
Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells. Infect Immun (2006) 0.95
Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob Agents Chemother (2005) 0.94
Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. J Crohns Colitis (2009) 0.92
Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect (2006) 0.91
Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease? AIDS (2010) 0.91
Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect (2011) 0.90
A black necrotic ulcer. Lancet (2003) 0.90
Buccal exposure to human papillomavirus type 16 is a common yet transitory event of childhood. J Med Virol (2003) 0.90
European perspective of 2-person rule for biosafety level 4 laboratories. Emerg Infect Dis (2009) 0.88
Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect (2005) 0.88
Development of a multi-pathogen oligonucleotide microarray for detection of Bacillus anthracis. Mol Cell Probes (2005) 0.88
Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis (2013) 0.88
The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J Infect (2012) 0.86
Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. Int J Infect Dis (2010) 0.85
Immunotherapy for fungal infections. Curr Opin Microbiol (2012) 0.85
Loss of expression and promoter methylation of SLIT2 are associated with sessile serrated adenoma formation. PLoS Genet (2013) 0.84
Q fever outbreak in industrial setting. Emerg Infect Dis (2004) 0.84
The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduct J (2008) 0.80
Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS (2006) 0.79
MMR immunisation after contact with measles virus. Lancet (2004) 0.78
In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Int J Antimicrob Agents (2004) 0.78
Case report: Eastern equine encephalitis virus imported to the UK. J Med Virol (2009) 0.78
Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis. J Acquir Immune Defic Syndr (2010) 0.77
Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. Clin Infect Dis (2009) 0.77
Treatment of tuberculosis in HIV-infected individuals. AIDS (2002) 0.75
Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis? Clin Infect Dis (2010) 0.75
Congenital rubella: down but not out. Lancet (2002) 0.75
Prevention of AIDS-associated cryptococcosis in resource-poor areas. Lancet Infect Dis (2011) 0.75